Αρχική World News FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma World News FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma Από Ogkologos - 14 Αυγούστου, 2025 671 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Working towards equal cancer care for everyone 2 Αυγούστου, 2023 Survival According Circulating Tumour DNA Status in the Study of Adjuvant... 10 Δεκεμβρίου, 2020 Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... 15 Οκτωβρίου, 2021 Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated... 12 Οκτωβρίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Woman Helps Students With Special Needs Achieve Success After Graduation What Survivors Should Know When Transitioning From Cancer Care to Primary... Women Diagnosed with Early Breast Cancer Since 2000 Have About a... Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,...
